Exact Sciences Launches Cancerguard™, First-of-Its-Kind Multi-Cancer Early Detection Blood Test (Business Wire)

Exact Sciences has launched Cancerguard™, a $689 multi-cancer early detection (MCED) blood test now available nationwide through Quest Diagnostics. Cancerguard screens for 50+ cancers — including colorectal, pancreatic, ovarian, liver, lung, stomach, and esophageal — with 64% overall sensitivity, 68% for six of the deadliest cancers, and 97.4% specificity to reduce false positives. Building on the success of Cologuard®, which transformed colorectal cancer screening, Cancerguard extends early detection to cancers with no recommended routine screening, aiming to shift diagnoses to earlier, more treatable stages and lower mortality.